Proactive Investors - Run By Investors For Investors

Proactive Investors One2One Investor Forum - London

Silence Therapeutics plc | Eden Research | Cello Health plc

The presentations will start at 6:00pm and finish at approx 8:00pm. After the presentations are complete the directors will also be available to take questions during a free canapé and wine reception. Details on the presenting companies can be found below.


This event is suitable for the following:

Sophisticated & private investors, private client brokers, fund managers, financial institutions, hedge funds, buy & sell side analysts and journalists.


The event is not suitable for people pursuing commercial opportunities.

Cello Health plc

RSS Portfolio


We are a global healthcare-focused advisory group comprised of a set of leading clinical, commercial advisory and digital delivery capabilities.

We currently service 24 of the top 25 pharmaceutical clients globally as well as a wide range of biotech, diagnostics, devices and other key non-healthcare clients.

We enable clients to differentiate their propositions and drive brand success in ever more complex global markets. We deliver our services through nearly 1,000 highly skilled professionals utilising latest thinking, technology and digital solutions.

Cello Health plc delivers its services from an office network in the UK, USA, and Asia, with hub offices in New York, Philadelphia, London, Edinburgh, Farnham and Cheltenham.

Market: AIM
52-week High/Low: 139.88p / 95.00p
Market Cap: 115.18M

View full company profile

Eden Research

RSS Portfolio


Eden provides sustainable solutions for crop protection, animal health and consumer products.

Like humans and animals, plants have developed defences against disease, pests and various other threats. Essential oils are one component of these defence systems and these oils contain active molecules that help fight against disease, oxidative stress and insect predators. Eden has developed a technology which encapsulates these active molecules in particles that slow their release over a period of days ensuring better levels of control and improving the efficacy of products for the plant protection, consumer products and animal health markets.

. Our focus is on protecting high-value crops, improving crop yields and value.
. Our products are based upon natural chemistries but deliver performance, ease of use, and cost on par with synthetic pesticides.
. Eden has partnered with Eastman Chemical for the commercialisation of its second product in nearly 30 countries.
. Eden has regulatory clearance in the top 3 wine producing countries worldwide.

Market: AIM
52-week High/Low: 16.50p / 7.50p
Market Cap: 22.84M

View full company profile

Silence Therapeutics plc

RSS Portfolio


Silence Therapeutics develops a new generation of medicines by harnessing the body’s natural mechanism of RNA interference, or RNAi, within its cells.

Our proprietary technology can selectively inhibit any gene in the genome, specifically silencing the production of disease-causing proteins. Using our enabling delivery systems, we have achieved an additional level of specificity by delivering our therapeutic RNA molecules exclusively to target cells. Silence’s proprietary RNA chemistries and delivery systems are designed to improve the stability of our molecules and enhance effective delivery to target cells, providing a powerful modular technology well suited to tackle life-threatening diseases.

Market: AIM
52-week High/Low: 206.00p / 49.50p
Market Cap: 34.82M

View full company profile
Copyright ©, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use